findmyKOL
Clinical trialNCT06249048RecruitingPhase 1/PHASE2Interventional

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

SponsorStrand Therapeutics Inc.Enrollment108Advanced Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Melanoma Institute Australia

    Wollstonecraft, Australia

    Recruiting
United States
  • Honorhealth Research and Innovation Institute

    Scottsdale, Arizona, United States

    Not, yet, recruiting
  • Nextgen Oncology

    Beverly Hills, California, United States

    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Not, yet, recruiting
  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

    Recruiting
  • the University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

    Recruiting
  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah, United States

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Keytruda®STX-001
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 May 2024
Primary completion
31 May 2027
Completion
30 Nov 2028
Last update posted
29 Oct 2025
Registered enrollment
108
Registry id
NCT06249048
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.